The actual studies
A curated index of peer-reviewed cannabis research from PubMed. Browse by condition, filter by study type (meta-analyses and RCTs lead). Every result links straight to the source on pubmed.ncbi.nlm.nih.gov. Re-indexed weekly.
★ Featured studies · with our plain-English read
Browse by condition
- IBD & Crohn's disease
Inflammatory bowel disease research. Cannabis as adjunct therapy for symptom management — pain, appetite, inflammation — and trials around disease-activity outcomes.
- Chronic pain
Cannabis for persistent and neuropathic pain — including back pain, neuropathy, fibromyalgia, and post-surgical pain. The most-studied therapeutic application.
- Anxiety
Cannabinoids — especially CBD — for generalized anxiety, social anxiety, and panic. Heavy attention to the biphasic dose-response curve.
- Multiple sclerosis
Cannabis-based medicine for spasticity, pain, and quality of life in MS. Sativex (nabiximols) is approved for MS spasticity in 25+ countries — the strongest regulatory acceptance to date.
- Epilepsy
Cannabidiol for treatment-resistant epilepsies including Dravet and Lennox-Gastaut syndromes. Epidiolex (purified CBD) received FDA approval in 2018.
- Chemo-induced nausea
Cannabinoids for chemotherapy-induced nausea and vomiting (CINV). Dronabinol and nabilone are FDA-approved for this indication.
- PTSD
Cannabis for post-traumatic stress disorder symptoms — nightmare suppression, hyperarousal, sleep. Mixed evidence; growing trial pipeline.
- Cancer
Cannabis as adjunct therapy in oncology — pain, appetite, sleep, nausea. Direct anti-tumor mechanism is preclinical and unproven in humans.
- Sleep disorders
Cannabis and cannabinoids for insomnia, sleep onset, and REM modulation. Patient surveys show heavy use for sleep; controlled trial evidence is thinner than the popular use suggests.